Treatment of chronic hepatitis B virus infection with rebavrin.

Kew, M. C.; Seftel, H C

doi:10.1136/bmj.1.6065.904

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serologic evaluations were not performed. In another study conducted in South Africa, ribavirin failed to clear HBsAg from the serum and did not improve biochemical values in 13 patients with chronic HBV infection [38]. Similarly, in a double-blind controlled trial conducted at the Royal Free Hospital, London, no effect of ribavirin could be detected in six patients with HBsAg-positive CAH either with regard to the hepatitis serology or the associated hepatic disease [36].…”

Section: Adenine Arabinoside (Ara-a Vidarabine)mentioning

confidence: 94%

Immunoprophylaxis and Treatment of Viral Hepatitis B

Seeff¹

1981

Semin Liver Dis

View full text Add to dashboard Cite

It is evident that new vistas have been opened with the advent of antiviral and other novel drugs. Most of the studies performed to date, however, have involved too few patients, have not been double-blinded, or have been entirely uncontrolled. In essence, these represent phase II studies. Because the HBsAg-carrier state is dynamic in that viral markers are generally in a state of flux, and because it is important to determine risk as well as benefit, no conclusions can be reached without an adequately designed double-blind, controlled study. At present, the most promising therapy seems to be the antiviral drugs, particularly interferon and Ara-A (or Ara-AMP). Still to be determined are the appropriate dose, appropriate duration of treatment, the extent of toxicity, and the validity of combination therapy. Also important is the development of simpler and less expensive ways of producing interferon. A potentially exciting and productive era appears about to open.

show abstract

Section: Adenine Arabinoside (Ara-a Vidarabine)mentioning

confidence: 94%

Immunoprophylaxis and Treatment of Viral Hepatitis B

Seeff¹

1981

Semin Liver Dis

View full text Add to dashboard Cite

show abstract

Ribavirin: An antiviral agent

Sidwell¹,

Robins²,

Hillyard³

1979

Pharmacology & Therapeutics

141

View full text Add to dashboard Cite

Ribavirin - current status of a broad spectrum antiviral agent

Snell¹

2001

Expert Opinion on Pharmacotherapy

181

104

View full text Add to dashboard Cite

Ribavirin is a very broad-spectrum virustatic antiviral agent, first synthesised in 1972. It is characterised by low toxicity apart from reversible anaemia, usually mild. Its multiple mechanisms of action mean that viral resistance rarely develops. It can be administered orally, intravenously, or via a nebuliser. It has shown varying degrees of clinical efficacy in a variety of human diseases including respiratory tract infections due to respiratory syncytial virus and influenza, measles, herpesvirus infections, HIV infection, Lassa fever, haemorrhagic fever with renal syndrome, and (in combination with IFN-alpha) chronic hepatitis C infection. It may well prove of value against other emerging exotic infections (e.g., West Nile virus, Nipah virus).

show abstract

Treatment of chronic hepatitis B virus infection with rebavrin.

Cited by 3 publications

References 0 publications

Immunoprophylaxis and Treatment of Viral Hepatitis B

Immunoprophylaxis and Treatment of Viral Hepatitis B

Ribavirin: An antiviral agent

Ribavirin - current status of a broad spectrum antiviral agent

Contact Info

Product

Resources

About